Heme-regulated inhibitor kinase (HRI), a eukaryotic translation initiation factor 2 alpha (eIF2α) kinase, plays critical roles in cell proliferation, differentiation, and adaptation to cytoplasmic stress. HRI is also a critical modifier of hemoglobin disorders such as β-thalassemia. We previously identified N,N'-diarylureas as potent activators of HRI suitable for studying the biology of this important kinase. To expand the repertoire of chemotypes that activate HRI, we screened a ∼1900 member N,N'-disubstituted urea library in the surrogate eIF2α phosphorylation assay, identifying N-aryl,N'-cyclohexylphenoxyurea as a promising scaffold. We validated hit compounds as a bona fide HRI activators in secondary assays and explored the contributions of substitutions on the N-aryl and N'-cyclohexylphenoxy groups to their activity by studying focused libraries of complementing analogues. We tested these N-aryl,N'-cyclohexylphenoxyureas in the surrogate eIF2α phosphorylation and cell proliferation assays, demonstrating significantly improved bioactivities and specificities. We consider these compounds to represent lead candidates for the development of potent and specific HRI activators.
Heme-regulated inhibitor kinase (n class="Gene">HRI), a eukaryotic translation initiation factor 2 alpha (eIF2α) kinase, plays critical roles in cell proliferation, differentiation, and adaptation to cytoplasmic stress. HRI is also a critical modifier of hemoglobin disorders such as β-thalassemia. We previously identified N,N'-diarylureas as potent activators of HRI suitable for studying the biology of this important kinase. To expand the repertoire of chemotypes that activate HRI, we screened a ∼1900 member N,N'-disubstitutedurea library in the surrogate eIF2α phosphorylation assay, identifying N-aryl,N'-cyclohexylphenoxyurea as a promising scaffold. We validated hit compounds as a bona fide HRI activators in secondary assays and explored the contributions of substitutions on the N-aryl and N'-cyclohexylphenoxy groups to their activity by studying focused libraries of complementing analogues. We tested these N-aryl,N'-cyclohexylphenoxyureas in the surrogate eIF2α phosphorylation and cell proliferation assays, demonstrating significantly improved bioactivities and specificities. We consider these compounds to represent lead candidates for the development of potent and specific HRI activators.
Authors: H Aktas; R Flückiger; J A Acosta; J M Savage; S S Palakurthi; J A Halperin Journal: Proc Natl Acad Sci U S A Date: 1998-07-07 Impact factor: 11.205
Authors: S S Palakurthi; R Flückiger; H Aktas; A K Changolkar; A Shahsafaei; S Harneit; E Kilic; J A Halperin Journal: Cancer Res Date: 2000-06-01 Impact factor: 12.701
Authors: Revital Yefidoff-Freedman; Jing Fan; Lu Yan; Qingwen Zhang; Guillermo Rodrigo Reis Dos Santos; Sandeep Rana; Jacob I Contreras; Rupam Sahoo; Debin Wan; Jun Young; Karina Luiza Dias Teixeira; Christophe Morisseau; Jose Halperin; Bruce Hammock; Amarnath Natarajan; Peimin Wang; Michael Chorev; Bertal H Aktas Journal: J Med Chem Date: 2017-06-19 Impact factor: 7.446
Authors: Nicholas Burwick; Michael Y Zhang; Pilar de la Puente; Abdel Kareem Azab; Teresa S Hyun; Melisa Ruiz-Gutierrez; Marilyn Sanchez-Bonilla; Tomoka Nakamura; Jeffrey J Delrow; Vivian L MacKay; Akiko Shimamura Journal: Leuk Res Date: 2017-01-12 Impact factor: 3.156
Authors: C Leah B Kline; A Pieter J Van den Heuvel; Joshua E Allen; Varun V Prabhu; David T Dicker; Wafik S El-Deiry Journal: Sci Signal Date: 2016-02-16 Impact factor: 8.192
Authors: Sandeep Rana; Yogesh A Sonawane; Margaret A Taylor; Smitha Kizhake; Muhammad Zahid; Amarnath Natarajan Journal: Bioorg Med Chem Lett Date: 2018-10-15 Impact factor: 2.823